Table 1.
Correlation between circ-ERBB2 expression and clinical characteristics in breast cancer patients
| Clinicopathologic parameters | N | circ-ERBB2 expression | p-value | |
|---|---|---|---|---|
| Low (%) | High (%) | |||
| Age (years) | ||||
| ≤ 40 | 8 | 3 (37.5%) | 5 (62.5%) | 0.750 |
| > 40 | 35 | 18 (51.4%) | 17 (48.6%) | |
| Tumor size (cm) | ||||
| ≤ 2 | 30 | 13 (43.3%) | 17 (56.7%) | 0.332 |
| > 2 | 13 | 8 (61.5%) | 5 (38.5%) | |
| Lymph node metastasis | ||||
| Negative | 20 | 14 (70.0%) | 6 (30.0%) | 0.010* |
| Positive | 23 | 7 (30.4%) | 16 (69.6%) | |
| Histological grade | ||||
| I | 11 | 7 (63.6%) | 4 (36.4%) | 0.214 |
| II | 14 | 8 (57.1%) | 6 (42.9%) | |
| III | 18 | 6 (33.3%) | 12 (66.7%) | |
| TNM stage | ||||
| I | 10 | 8 (80.0%) | 2 (20.0%) | 0.090 |
| II | 16 | 8 (50.0%) | 8 (50.0%) | |
| III | 13 | 4 (30.8%) | 9 (69.2%) | |
| IV | 4 | 1 (25.0%) | 3 (75.0%) | |
| HER2 status | ||||
| Negative | 20 | 15 (75.0%) | 5 (25.0%) | 0.001** |
| Positive | 23 | 6 (26.1%) | 17 (73.9%) | |
TNM: tumor-node-metastasis
*P<0.05
**P<0.01